AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 10, 2026, 8:30 AM ET CRISPR Therapeutics senior management will take part in a fireside chat at the 2026 Jefferies Global Healthcare Conference on November 17, 2026. AI-generated summary · Source: company release
Nasdaq: $CRSPBiotechnologyCommercial, clinical and financing risk

CRSP Stock Hub: CRISPR Therapeutics News, CASGEVY and CTX310

CASGEVY is a commercial gene therapy, and Vertex’s reported sales offer a direct measure of product uptake. CRISPR Therapeutics reports its own results under a collaboration that shares net program economics. The company is also developing investigational cell therapies and cardiovascular medicines whose early data answer different clinical questions. September liquidity includes convertible financing, so collaboration economics, development spending and potential dilution each have a place in evaluating the balance sheet.

Last updated: November 20, 2026Financial period: quarter ended September 30, 2026Currency: U.S. dollars
Full research report · PDF
CRISPR Therapeutics ($CRSP), research updated November 20, 2026
16 pages on CASGEVY, clinical evidence, cash flow and capital structure. For personal use only: redistribution prohibited.
Get the report (PDF)
Next company-disclosed window
Second half of 2026 · CTX611 phase 2 update

Completed enrollment and study context.

CRISPR Therapeutics CRSP daily stock chart
Daily chart $CRSP. Source: Finviz, for information only. Interactive chart with bull and bear scenarios on JC Just Charts →

CRSP stock at a glance

Chart analysis · JC
Technical chart analysis of $CRSP with bull and bear scenarios on JC Just Charts.
Vertex Q3 CASGEVY sales
$99.2M
CRISPR Q3 collaboration expense
$41.284M
September cash and securities
$2.277B
Nine-month operating cash used
$282.079M
Principal of 2031 notes
$600M
September common shares
96.856M

Where CRISPR Therapeutics stands now

Three operating questions anchor the stock analysis. The first is whether Vertex’s sales can continue to grow as the patient pathway and country-level coverage advance. The second is whether CRISPR’s share of the profit and loss improves enough to absorb some of the cost of other clinical development. The third is whether early signals from the investigational pipeline justify the scale and timing of future spending. Those questions use separate evidence. Product sales are reported by Vertex, collaboration figures are reported by CRISPR, and the investigational trials supply their own endpoints, sample sizes and follow-up. CRISPR September 10-Q · Vertex September-quarter results

A broad clinical portfolio gives the company more than one way to make progress. It also puts more than one program in competition for investment. A biomarker in an early cardiovascular study can be useful for selecting a next study, and an autoimmune cohort can inform a differentiated clinical program. The commitments required to expand either program will depend on its own development pathway. The balance sheet can finance those decisions over time, while the debt and common share counts provide a separate measure of how that funding was obtained and what claims may follow. CRISPR November results and pipeline update

Constructive case

Higher CASGEVY sales eventually improve collaboration settlements while funded studies produce durable results.

Cautious case

Shared commercial costs and clinical commitments consume funds while later evidence takes longer to emerge.

Latest CRISPR Therapeutics news

Nov 10, 2026

CRISPR Therapeutics to present at the 2026 Jefferies Global Healthcare Conference

CRISPR Therapeutics announced that members of its senior management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Tuesday, November 17, 2026. A live webcast will be available on the Events & Presentations page of the Investors section of the Company's website. A replay will be archived on the website for 14 days after the presentation.

Nov 9, 2026

CRISPR Therapeutics presents Phase 1b CTX310 data showing ANGPTL3 and triglyceride reductions

CRISPR Therapeutics presented Phase 1b clinical data for CTX310 at the American Heart Association (AHA) Scientific Sessions 2026 in a late-breaking oral presentation. A single-course treatment produced a mean reduction from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides (TG) at Day 30 in patients with severe hypertriglyceridemia (sHTG). CTX310 was well tolerated, with no treatment-related serious adverse events and no clinically relevant elevations in liver transaminases.

Nov 8, 2026

CRISPR Therapeutics provides update on zugo-cel in refractory rheumatologic autoimmune diseases

CRISPR Therapeutics provided an update on zugo-cel, its allogeneic CD19-targeted CAR-T therapy, in a Phase 1 basket trial in refractory rheumatologic autoimmune diseases. At Month 3, 83% (5/6) of systemic sclerosis patients receiving standard lymphodepletion achieved an rCRISS-25 response, and all nine idiopathic inflammatory myopathy patients achieved a moderate or major TIS response. As of October 15, 2026, 21 patients had been dosed, with no cytokine release syndrome above Grade 2 and no ICANS or IEC-HS reported.

Nov 4, 2026

CRISPR Therapeutics to present zugo-cel clinical data in large B-cell lymphoma at ASH

CRISPR Therapeutics announced that clinical data from the ongoing Phase 1/2 trial of zugo-cel in patients with relapsed or refractory large B-cell lymphoma will be presented in an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 12 to 15, 2026. The presentation is Abstract Number 706, scheduled for Sunday, December 13, 2026. A copy will be available at www.crisprtx.com once the presentation concludes.

Nov 4, 2026

Wells Fargo cuts CRISPR Therapeutics price target to $70

Wells Fargo lowered its price target on CRISPR Therapeutics (CRSP) to $70. Analyst action reported by the press; it is the bank's view, not Merlintrader's.

Nov 2, 2026

CRISPR Therapeutics announces appointment of Siva Sakhamuri as Chief Technical Officer

CRISPR Therapeutics appointed Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer, effective immediately. Dr. Sakhamuri brings about 30 years of technical operations and manufacturing leadership experience across biologics, vaccines, oligonucleotides, RNA therapeutics and lipid nanoparticle (LNP) delivery. He most recently served as Chief Technical Officer of Orna Therapeutics from 2024 until its acquisition by Eli Lilly and Company in 2026. From 2016 to 2021, he was Vice President, Manufacturing at Alnylam Pharmaceuticals.

Catalyst calendar

  • July 1, 2026 · FDA expanded CASGEVY eligibility to younger pediatric patients. Approved.
  • November 2, 2026 · September-quarter results. Published.
  • November 8, 2026 · Zugo-cel autoimmune update. Reported.
  • November 9, 2026 · CTX310 severe hypertriglyceridemia data. Reported.
  • Second half of 2026 · CTX611 phase 2 update. Company estimate.
  • March 1, 2031 · Convertible note maturity. Contractual date.

Clinical and commercial milestones.

CRISPR Therapeutics deep dive: the full analysis

The Merlintrader Research Library collects our dated biotech stock research reports.

01 Three paths for the commercial and clinical portfolio

Bull case. CASGEVY continues to convert more eligible patients into treatment, and the shared expenses reported by CRISPR decline as net program economics improve. Early clinical signals in cardiovascular disease and autoimmunity are supported by more participants, clearer endpoints and longer follow-up. Those advances allow the company to prioritize programs with defensible evidence and to fund a substantial part of the work from existing resources.

Base case. CASGEVY sales increase while the pathway from referral to therapy remains lengthy and remains sensitive to country-level access. Collaboration spending and independent research costs continue even when product sales improve. The company advances a selection of programs through further cohorts and clinical stages. Investor confidence moves with the quality of the next evidence rather than a single early biomarker or cohort disclosure.

Bear case. Treatment uptake is constrained by referral, reimbursement or capacity, and the reported collaboration expense remains meaningful. Larger or longer studies are needed to establish the significance of early clinical findings. The company then continues to use cash for development while the path to sustained operating funding remains less certain. Capital raised through issued securities protects the development schedule but can increase senior claims or dilute common shareholders.

What would falsify this reading

A sustained improvement in net collaboration expense alongside rising partner product revenue would support the commercial case. Rising sales without a durable change in shared economics would leave a question about the ongoing cost structure. A clinical update with longer follow-up, transparent sample definitions and results on a prespecified endpoint can change the estimate of development risk. Related observations about safety and retention matter because they determine who can proceed through a program and how much confidence a reader should place in the reported efficacy population. September 10-Q · CRISPR November results

02 CASGEVY and the meaning of the clinical endpoints

CASGEVY is exagamglogene autotemcel, a cell therapy for eligible patients with sickle cell disease or transfusion-dependent beta thalassemia. These are separate diseases and use different pivotal endpoints. In severe sickle cell disease, the clinical objective studied by Frangoul and colleagues included freedom from severe vaso-occlusive crises for a specified continuous period. In transfusion-dependent beta thalassemia, Locatelli and colleagues studied transfusion independence under the trial’s definition. A response rate in one indication should be stated with its own outcome, follow-up and population. Frangoul et al., New England Journal of Medicine 2024 · Locatelli et al., New England Journal of Medicine 2024

Early published work first described treatment experience in two patients with the two different diseases. It helped establish the clinical rationale for later trials. Broader trials built on those observations with more participants and prespecified measurements. The early case experience, pivotal studies and evidence in younger patients supply different kinds of information. Pooling those results would obscure how the populations were selected and how each report assessed benefit. Frangoul et al., New England Journal of Medicine 2021

The pediatric report in the New England Journal of Medicine studied 15 children with transfusion-dependent beta thalassemia and 11 with sickle cell disease who received exa-cel. The reported median follow-up was approximately 16 and 17 months, respectively. Those numbers concern the treated groups in the publication and are separate from the age criteria on the product label. The FDA approved an expansion to eligible US patients from age two in July 2026. Age eligibility can enlarge the number of patients potentially referred, while eligibility for treatment depends on the authorized terms and an individual assessment. Frangoul et al., New England Journal of Medicine 2026 · FDA July 1 approval letter

The publicly reported clinical data involve individualized treatment and monitoring. The operational pathway includes specialist referral, evaluation and access to a qualified treatment center. Product authorization establishes what may be marketed in a jurisdiction. It does not create an immediate treatment slot for each eligible patient or establish identical payer arrangements across countries. The company and its partner report developments stage by stage. Authorized regions, patients beginning the pathway and sales at the end of it should be identified separately. FDA CASGEVY product information · Vertex September-quarter results

03 Commercial reporting and the Vertex economics

Vertex reported $99.2 million of CASGEVY net product revenue in the September quarter, up from $16.9 million in the year-earlier quarter. It reported $218.5 million for the first nine months of 2026, compared with $61.5 million in the same period of 2025. These are Vertex-reported net product figures. They are useful indicators of commercialization and belong under the partner’s reporting. CRISPR Therapeutics does not report a matching product-sales line in its September income statement. Vertex September-quarter results · CRISPR September 10-Q

Under the amended collaboration, Vertex leads CASGEVY, and the agreement allocates 60% of net profits and net losses to Vertex and 40% to CRISPR Therapeutics. Those percentages apply to the net economics described in the agreement. Multiplying Vertex sales by 40% would not give CRISPR’s reported revenue or a reliable measure of cash received. Identifying the shared costs and the accounting presentation is essential. CRISPR reported net collaboration expense of $41.284 million in the September quarter, down from $57.115 million in the year-earlier period. The company attributed the change primarily to an increase in its share of CASGEVY revenue. September 10-Q, Note 6 and MD&A

CRISPR separately reported $12.323 million of collaboration revenue in the September quarter. The filing says approximately $12.3 million was previously deferred revenue under an amendment to an earlier Vertex collaboration. It was recognized following notice that Vertex would not exercise an option on a specified target under that amendment. That recognition belongs to a different agreement and event from the quarterly partner sales and their shared expenses. A reader can avoid double counting by following Vertex sales, CASGEVY net collaboration expense and other collaboration revenue as three separate measures. September 10-Q, Note 6 and statements of operations

04 The CTX310 cardiovascular update

On November 9 CRISPR reported early phase 1b data for CTX310 in a dedicated severe hypertriglyceridemia cohort. Ten treated participants, including one from phase 1a, had at least 30 days of follow-up by the cutoff. The company reported mean reductions from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides at day 30. The median pretreatment triglyceride level was above 1,000 mg/dL. Seven participants had reached at least 90 days of follow-up. The sample and observation period frame the result. A reduction in biomarkers is a clinical observation, while a reduction in health events such as pancreatitis requires separate evidence suited to that outcome. November 9 company release

The phase 1b announcement described one grade 2 infusion reaction that resolved and reported no treatment-related serious adverse events or treatment-related events at grade 3 or higher by cutoff. Those are the sponsor’s observations in this cohort. A study with ten participants gives limited information about the frequency of uncommon events, and its safety findings are not transferable to all indications being studied. The company reported separate regulatory designations related to severe hypertriglyceridemia and elevated low-density lipoprotein cholesterol. Such designations affect aspects of the development process, while the study evidence supports its own limited conclusions. November 9 company release

An earlier phase 1 report in the New England Journal of Medicine examined the observed changes in lipid measures and safety in its own study population. The dedicated severe hypertriglyceridemia cohort has different baseline characteristics and contributes different evidence. In analyzing the opportunity, participants’ initial lipid levels, timing and background treatment all affect what the results mean. A broader study can test how consistently the response appears, how long it persists and which additional measures would be needed to support use in a defined patient population. Laffin et al., New England Journal of Medicine 2025

05 Zugo-cel in autoimmune disease

The November 8 sponsor release described results both for a systemic sclerosis cohort and for the broader rheumatology basket. These had different cutoffs. At July 21, seven patients with systemic sclerosis had at least three months of follow-up. Of six participants who received standard lymphodepletion, five met the revised Composite Response Index in Systemic Sclerosis 25 response at month three, including two who met the more stringent 50 criterion. The seventh participant received reduced lymphodepletion and showed changes in individual components. Those outcomes should retain their separate denominators. November 8 company release

The October 15 cutoff covered 21 dosed participants across systemic lupus erythematosus, systemic sclerosis and idiopathic inflammatory myopathy. The company said two of three evaluable patients with lupus maintained drug-free remission by DORIS criteria through at least month nine. For the nine inflammatory myopathy patients the sponsor reported moderate or major improvement by that cohort’s Total Improvement Score. These are disease-specific and exploratory observations. Applying a common percentage across them would hide the different criteria and follow-up. The company also reported no dose-limiting toxicity or several specified serious safety outcomes by the cutoff; a small uncontrolled safety population provides preliminary evidence. November 8 company release

Published work in autoimmune cell therapy offers context for the kinds of questions raised by this program. Müller and colleagues described an autologous CD19 cell-therapy case series with follow-up across multiple autoimmune conditions. Wang and colleagues reported a small separate experience with allogeneic therapy. Each study had its own product, population and observation window. The papers help frame durability, safety and feasible care settings, while the evidence for zugo-cel comes from its own prospective study and sponsor disclosures. Müller et al., New England Journal of Medicine 2024 · Wang et al., Cell 2024

06 Distinct clinical programs and the order of evidence

CRISPR’s November results describe ongoing development in several cardiovascular indications. CTX340 is being studied for refractory hypertension, and CTX321 is in development in connection with elevated lipoprotein(a). Separate programs require separate evidence. A reduction in triglycerides in a CTX310 study has no direct bearing on a blood-pressure outcome or on the effect of treating elevated lipoprotein(a). Each program will need an appropriate evidence package, a population specific to that problem and adequate safety observation. Publicly reported enrollment or entry into a clinical study is a development milestone before it is an outcome. November quarterly pipeline update

For alpha-1 antitrypsin deficiency, the company describes CTX460 as an ongoing phase 1 program. As with other early programs, a plausible therapeutic rationale can explain the decision to conduct a first clinical study. The prospective question is what the study actually shows about participants and measurable outcomes. The spending required to advance a portfolio depends in part on whether one program can move forward on its current evidence or needs additional cohorts and observation. The company has identified these programs separately in the November update. November quarterly pipeline update

The zugo-cel program also reaches beyond the rheumatology basket. The sponsor describes separate studies in hematologic and neurologic autoimmune disease, along with work in B-cell malignancies and a separate combination approach in aggressive B-cell lymphomas. These are different clinical settings. The suitability of clinical outcomes and follow-up cannot be inferred from the systemic sclerosis report alone. Where a company discusses results under a common product name, its disclosures should still be read against the protocol and the patients studied in each case. CRISPR November results · November 8 company release

PHASE 1

CTX340

Study ongoing in refractory hypertension.

EARLY DEVELOPMENT

CTX321

IND- or CTA-enabling studies for elevated lipoprotein(a).

PHASE 1

CTX460

Study ongoing in alpha-1 antitrypsin deficiency.

EARLY CLINICAL

Zugo-cel

Phase 1 autoimmune studies and a phase 1/2 study in B-cell malignancies.

PHASE 2

CTX611

Knee arthroplasty study enrollment complete.

07 CTX611 and the Sirius collaboration

CRISPR said it completed enrollment in the phase 2 CTX611 study in participants undergoing total knee arthroplasty, with an update expected in the second half of 2026. The study is tied to a specific surgical setting. Any later report on efficacy or bleeding will have to be assessed with its own comparator, definitions and follow-up. Enrollment completion tells readers that participants have been recruited for the study. Endpoint assessment and the communication of results occur afterward. November company update

An earlier randomized study by Büller and colleagues evaluated a different Factor XI-directed product in knee arthroplasty. Its composite efficacy endpoint included thrombi seen on routine venography as well as clinically apparent events. That distinction matters when interpreting a future results release. A change in a composite can be driven by one of its more frequently observed components. The counts for symptomatic events and clinically important bleeding help readers judge the practical implications. The paper establishes context for the choice of the surgical setting and provides no efficacy estimate for CTX611. Büller et al., New England Journal of Medicine 2015

The May 2025 agreement with Sirius includes collaboration on CTX611 and opportunities for CRISPR to pursue qualifying license options for certain additional targets. The companies describe equal sharing of relevant CTX611 costs and profits under their agreement, with separate responsibilities in the US and greater China. A potential future program under an option is a contractual possibility. It should be distinguished from a study that has already started or from an approved product. The contract defines when the companies incur obligations and which costs are shared. September 10-Q, Note 6 · November update

This agreement also affects the September financial statements. Acquired in-process research and development expense of $11.675 million in the quarter primarily reflected a development milestone under the Sirius agreement. The segment disclosures separately report $5.427 million in net Sirius collaboration expense within management’s segment expense categories. That segment line is part of a separate view of consolidated spending. It should not be added to the consolidated R&D expense total a second time. Distinguishing milestones, shared development costs and potential option payments helps explain how clinical work affects several financial lines. September 10-Q, Note 6, segment and operations disclosures

08 Quarterly operations and the reported loss

CRISPR reported $12.669 million of total revenue for the quarter, including $346,000 of grant revenue. Total operating expense was $142.714 million. That includes consolidated R&D, acquired in-process R&D, general and administrative spending, and net collaboration expense. Other income partly offset the operating loss, leaving a $111.437 million net loss. In the year-earlier quarter operating loss was slightly wider but other income was higher, leaving a smaller net loss of $106.441 million. The operating and net lines offer different comparisons because their components moved in different directions. September 10-Q, statements of operations

USD millionsQ3 2026Q3 20259M 20269M 2025
Collaboration revenue12.323—23.323—
Grant revenue0.3460.8890.9852.646
Total revenue12.6690.88924.3082.646
Research and development71.88858.902207.614201.280
Acquired in-process research and development11.675—14.14896.253
General and administrative17.86716.93152.60355.143
Net collaboration expense41.28457.115127.505159.777
Total operating expenses142.714132.948401.870512.453
Operating loss(130.045)(132.059)(377.562)(509.807)
Other income, net18.68226.23753.91361.841
Income tax expense(0.074)(0.619)(1.873)(3.020)
Net loss(111.437)(106.441)(325.522)(450.986)

Acquired in-process R&D was lower across the nine months than in 2025, even though the quarter included a new expense related to the Sirius program. The prior year included expenses incurred upon entering the collaboration. A one-year comparison of the aggregate expense can therefore reflect when the company enters agreements and recognizes milestones. Independent development expense can still rise as the company advances its programs. For estimating spending needed in future periods, the milestone and portfolio effects are worth tracking separately. September 10-Q, MD&A

09 Cash use and the securities portfolio

The September balance sheet reported $192.027 million of cash and cash equivalents, $2.080521 billion of current marketable securities and $4.021 million of noncurrent marketable securities. Together they amount to $2.276569 billion before restricted cash (Merlintrader calculation). Restricted cash totaled $8.006 million, of which $0.377 million was recorded in current assets and $7.629 million in noncurrent assets. Adding restricted cash to cash and equivalents gives $200.033 million (Merlintrader calculation), the closing cash measure used in the cash-flow statement. At year-end 2025 cash and marketable securities totaled about $1.976 billion. The March note issuance was an important source of incremental funding. Liquidity increased on the broader balance-sheet measure while the cash and equivalents line itself fell, in part because cash was invested in marketable securities. September 10-Q, balance sheets and statements of cash flows

Operating cash use was $282.079 million in the nine months against $252.461 million in the comparable 2025 period. Operating cash use and capital expenditures together were $283.645 million before investment activity (Merlintrader calculation). The fact that net loss improved over nine months while operating cash use increased shows why the income statement is insufficient for funding analysis. The cash-flow statement reconciles the loss with adjustments such as equity compensation, changes in deferred revenue and certain noncash expenses. Working capital and collaboration receipts also affect the timing of cash. September 10-Q, cash-flow reconciliation

Cash-flow line, USD millionsNine months 2026Nine months 2025
Net cash used in operating activities(282.079)(252.461)
Net cash used in investing activities(480.488)(69.004)
Net cash provided by financing activities603.542309.612
Exchange rate effect(0.020)0.094
Net change in cash, equivalents and restricted cash(159.045)(11.759)

Cash used in investing included purchases of marketable securities. Maturities and sales of securities provided partial offsets and should be read with the closing portfolio balance. Net financing cash of $603.542 million included the March debt issue net of issuance costs, as well as other smaller issuance-related flows. The aggregate cash decline in the table applies to cash, equivalents and restricted cash. It does not give the change in the broader cash-and-securities measure reported in the November results. September 10-Q, statements of cash flows

The November 2 filing for the September quarter said existing cash, cash equivalents and marketable securities would enable CRISPR to fund operating expenses and capital expenditures for at least the next 24 months, excluding future proceeds from collaboration agreements and license arrangements. That estimate reflects a spending plan at the filing date. A major change in the pace of clinical development or the company’s commitments could change actual cash use. It is helpful to read the disclosed assumption alongside the cash-flow table and the contract terms. The nine-month cash-flow figure spans different payments and expense timing and makes a useful historical comparison, while management’s funding estimate refers to future operations. September 10-Q, liquidity and capital resources

10 Convertible debt and what the maturity means

In March 2026 CRISPR issued $600 million principal of convertible senior notes. The company reported about $585.4 million of net cash proceeds from issuance and carried the notes at $586.934 million at September 30. The difference between the principal amount and the carrying value reflects unamortized issuance costs. That balance will accrete toward principal as issuance costs are amortized. The stated annual coupon is 1.7308%. The filing describes an effective rate to investors of 1.125% after applicable Swiss withholding. Cash interest is payable semiannually. The notes mature March 1, 2031 unless earlier converted, redeemed or repurchased according to their terms. September 10-Q, Note 8

The initial rate is 13.0617 common shares per $1,000 of principal. Applied to the full original issue, the rate corresponds to 7,837,020 underlying shares before contractual adjustments (Merlintrader calculation). This describes the conversion exposure, not an increase in September shares outstanding. Upon conversion CRISPR delivers common shares. Holders can elect to convert before maturity subject to the indenture, including its conversion freeze period. Redemption or repurchase under the contract and repayment of outstanding principal at maturity can require cash. The financial effect therefore depends on how much principal is converted before maturity and whether any other right under the indenture is exercised. September 10-Q, Note 8

The proceeds and the obligations arose in the same transaction. The higher September securities balance gives management more capacity to complete clinical work. The balance sheet also now carries an unsecured claim on future resources. One comparison useful for funding analysis is between the recurring operating cash requirement and the amount of liquidity management would want to preserve through a delayed clinical or commercial milestone. The operating requirement could rise during confirmatory development or fall if collaboration settlements improve. A contractual maturity schedule leaves time to plan for such changes. It also puts a boundary on a model that assumes CRISPR can devote the entire securities portfolio to development. September 10-Q, liquidity and capital resources

The indenture also provides for additional shares under specified circumstances. The initial maximum stated in the filing is 11,363,580 shares, compared with the 7,837,020 attributable to the initial conversion rate. The maximum and the initial amount describe alternative outcomes for the same $600 million issue. The difference is 3,526,560 shares (Merlintrader calculation). The maximum is relevant to an assessment of capital structure exposure even though its realization depends on conditions in the indenture. The share counts refer to conversion under the contract. They do not specify the number of shares ultimately used to settle an actual conversion. September 10-Q, Note 8

11 Common shares and ownership filings

There were 96,855,526 common shares outstanding at September 30. The company had issued 96,930,842 and held 75,316 in treasury. The cover of the filing reports 97,000,813 outstanding at October 30, a rise of 145,287 between the two reporting dates (Merlintrader calculation). The cover gives a subsequent point-in-time count. The weighted-average share figure used for loss per share is a different measure. Since the company made a loss, potentially dilutive instruments can be excluded from the diluted earnings-per-share denominator as anti-dilutive. Their exclusion from that table leaves their potential future effect on actual shares outstanding intact. September 10-Q, cover, balance sheets and net loss per share note

Ownership measureWhat it describes
Period-end common sharesCommon shares outstanding on the balance-sheet date, excluding treasury shares
Cover-page share countCommon shares outstanding on a later specified day
Weighted-average sharesThe period denominator used in the income statement
Underlying convertible sharesContractual share exposure contingent on conversion terms and settlement
Equity compensationAwards with vesting and, where applicable, exercise terms

The filing also discusses share-based compensation as part of reported expenses. Expense recognition measures the portion allocated to the period under accounting rules. The actual share consequences depend on awards vesting and whether holders exercise any options. A cash-flow reconciliation then adds back noncash compensation to reconcile the reported loss to operating cash. This accounts for a timing and classification difference between cash usage and the economic cost of compensating staff with equity. A balance-sheet review needs both views. September 10-Q, statements of cash flows and share-based compensation

Note 11 enumerates instruments excluded from diluted EPS in the reporting period. It lists 6,647,199 options, 1,976,199 unvested restricted stock awards and units, 5,179 shares issuable under the employee purchase plan, and the conversion exposure at the initial rate. Each has a distinct path to issuance. An option can expire unexercised and restricted awards can be forfeited. The employee share purchase plan is another source of potential issuance on its own terms. A share model should preserve these distinctions when estimating ownership sensitivity. The reported amounts also predate the subsequent October share count. September 10-Q, Note 11

The at-the-market program remains another potential source of financing. The company disclosed $557.2 million of remaining gross capacity at the September reporting date and reported no sales under the program during the 2026 quarter or nine months. The history under that program included approximately 0.7 million shares and $42.3 million of proceeds net of commissions and fees. The remaining dollar capacity is an authorization that the company can draw upon through equity sales. It carries no fixed number of shares because a future transaction would take place at the prices available when shares were sold. Financing analysis can therefore record the remaining capacity without assuming any additional shares in the current outstanding count. September 10-Q, shareholders’ equity note and liquidity discussion

The November 19 Form 4 records a gift of 100,000 shares on November 17. A separate November 6 Form 4 records 90,000 options and 40,000 restricted stock units granted on November 4. These filings describe different transactions with different implications. The gift is a reported transfer of ownership. The award describes compensation subject to its own award conditions. Schedule 13G disclosures use still other definitions: they report beneficial ownership and can show shared voting or dispositive authority across related accounts. The two insider reports provide the transaction and security codes. November 19 Form 4 · November 6 Form 4

ARK’s November 13 amendment reported 10,056,844 shares of beneficial ownership, or 10.40%. The same shares appear across the two reporting persons’ cover pages. State Street’s November 10 filing reported 4,994,047 beneficially owned shares, or 5.2%. The November 16 Orbis and Allan Gray amendment reported a joint position of 4,519,261 shares, or 4.7%, in Item 4 and reported that the position had fallen below the 5% reporting threshold. All three filings report positions as of September 30, 2026. ARK amendment · State Street filing · Orbis and Allan Gray amendment

12 Market liquidity and the ability to trade

Nasdaq’s October 30 short-interest settlement shows 17,189,067 shares short and reported average daily volume of 1,312,645. The published days-to-cover figure is 13.09. The quotient compares a stock of open short positions with an average rate of trading activity. Trading activity on a day with clinical data or an FDA decision can differ substantially from the reference average. Because the short-interest figure has its own settlement date, it cannot tell readers how many positions remain open several weeks later. Nor does the figure disclose why any particular holder established a short position. Nasdaq short interest and volume

For the Health Score, the Nasdaq listing gives CRSP access to an established trading venue. A substantial number of shares trade on a typical day in the referenced period, while relatively high days to cover implies that the position measure is large compared with normal market activity. Both observations can be true simultaneously. Portfolio changes with large orders can require trading over more than one session. A reader evaluating business funding should leave that question distinct from whether CRISPR has sufficient cash and securities to support clinical work. The exchange statistic is relevant to transactions in the shares, whereas the financial statements describe funding available to the issuer. Nasdaq CRSP short-interest history · September 10-Q, listing and liquidity

13 What the next update could establish

For CASGEVY, the next company and partner disclosures can help readers judge whether higher recognized sales are carrying through to the collaboration balance. The sales figure is one input. The cash effect will also depend on timing, eligible expenses and the contractual accounting. The 10-Q discloses $221.8 million of costs from 2022 through 2024 that were deferred under the amended agreement and that may be recouped by Vertex only under specified conditions involving profitability and a yearly limit. This is a historical cost-recovery provision. The terms matter when considering how sustained growth in sales could translate into cash available to CRISPR. September 10-Q, Note 6, Vertex agreement

For CTX611 the sponsor has given a window in the second half of 2026 after announcing completed enrollment. For CTX310 the company update remains early clinical evidence. Increasing the number of participants at meaningful follow-up points will be informative because a short observation measures a different question from whether a biomarker effect is durable. An estimate at the next cutoff should be accompanied by the number evaluated at the relevant visit and the disposition of participants who are missing observations. Longer follow-up also gives safety observations time to accumulate. The useful denominator is the one attached to the question being asked in that report. CRISPR November update

For zugo-cel, disease-specific disclosure will carry more information than an increase in the overall number of participants. The rheumatology cohorts have different clinical endpoints. A cohort’s interpretation depends on active disease at entry, prior treatments, time since infusion and concomitant medication. The total across the basket describes recruitment. Each indication reports clinical outcomes separately. As additional results arrive, readers should look for whether the protocol defines an evaluable population prospectively and whether responses continue after the cutoff used in the prior presentation. Company autoimmune update

14 A framework for the next financial comparison

An increase in total revenue attributable to current grants has different implications from an increase attributable to a release of deferred collaboration consideration. When future results arrive, it will help to trace recognized revenue to the note that specifies the source of the transaction. Segment expense disclosures can help identify commercial collaboration costs and milestones, while the consolidated income statement gives the operating total without double counting. The balance sheet and cash-flow statement then show whether a recurring activity is consuming fewer resources, whether a payment simply settled in a different quarter, or whether external financing raised the reported liquidity. September 10-Q, revenue recognition, segment and cash-flow disclosures

The four questions are straightforward. What sales did Vertex report for CASGEVY? What obligation or recovery did CRISPR recognize under the arrangement? How much cash did operations consume? Which obligations would still exist if clinical programs took longer than expected? Changes in those four measures can be evaluated without assuming that a dollar of Vertex sales produces an immediate, proportionate improvement in CRISPR’s cash flow. They also allow readers to compare periods when one-time license events or spending milestones make the aggregate income statement less comparable. Vertex quarterly results · September 10-Q

Merlintrader Health Score · $CRSP

3.15out of 5
Balance sheet and runway · 30%4.0

September cash and securities totaled approximately $2.277 billion. Management expects the resources to cover operating expenses and capital spending for at least 24 months. Liquidity and operating cash flow.

Catalyst · 30%3.0

CASGEVY has expanded its U.S. indication. The next CTX611 update has a sponsor window, while CTX310 and zugo-cel need more evidence. Upcoming evidence.

Dilution · 20%2.5

Convertible notes, equity awards and remaining ATM capacity are distinct sources of potential issuance. Common and potential shares.

Liquidity · 10%2.5

CRSP is listed on Nasdaq. At the October 30 settlement, short interest of 17,189,067 shares compared with 1,312,645 average daily shares traded, or 13.09 days to cover. Market liquidity.

Execution · 10%3.0

The Vertex launch has expanded and the CRISPR portfolio includes active studies. Commercial collaboration expense and developing clinical evidence remain important. Collaboration economics.

Assessed November 20, 2026. Merlintrader calculation: 4.0 × 30% + 3.0 × 30% + 2.5 × 20% + 2.5 × 10% + 3.0 × 10% = 3.15 out of 5.

Red flags to track

  • Net collaboration expense persists without a corresponding improvement in cash settlement, even as Vertex sales rise.
  • Follow-up in early studies expands more slowly than enrollment, preventing a clean assessment of safety or durability.
  • Development milestones trigger cash needs sooner than budgeting assumptions imply.
  • New financing adds potential share issuance or increases the claims on future cash.
  • Capacity, reimbursement or patient access limits how quickly regulatory expansion translates into completed treatment.

CRSP Stock FAQ: CRISPR Therapeutics Questions Answered

What does CRISPR Therapeutics do?

The company develops gene-based medicines. It shares the economics of CASGEVY with Vertex and develops investigational programs in cardiovascular disease, immunology and related areas. Product marketing and regulatory roles differ across programs. September 10-Q

Where do CASGEVY sales appear?

Vertex reports CASGEVY product sales. CRISPR reports its side of the agreement through collaboration accounting, including its share of net commercial results. For the reported quarter the relevant CRISPR amount was an expense. Vertex results · September 10-Q, Note 6

What can dilute CRSP common shares?

Future equity issuance, vesting or exercise of applicable equity awards, and share settlement on conversion of eligible notes can change common shares outstanding. The share count in the filing reflects actual issuance through its stated date. September 10-Q

What is the next clinical update to watch?

In its November results the company said it expected an update from the CTX611 phase 2 study in the second half of 2026. The disclosure did not name a calendar date. The current milestones are listed in the catalyst calendar above. CRISPR November update

How are cash and securities different from operating cash flow?

Cash and securities measure an asset balance at a given date. Operating cash flow describes activity over a period. Financing proceeds can increase the asset balance while operations use cash. September 10-Q

What does the new CTX310 evidence show?

The sponsor reported early changes in ANGPTL3 and triglycerides in participants with severe hypertriglyceridemia. The reported results are clinical biomarker observations from a small study. CRISPR CTX310 update

What does RMAT designation establish?

The FDA describes Regenerative Medicine Advanced Therapy designation as a means of facilitating development and review after the applicable criteria have been met. The designation can provide opportunities for interaction with the agency. Approval for a particular use requires a separate regulatory decision based on the evidence submitted. FDA guidance on expedited programs for regenerative medicine therapies

What did the FDA do in July?

The FDA expanded the US CASGEVY indication to eligible younger pediatric patients with sickle cell disease with recurrent vaso-occlusive crises or transfusion-dependent beta-thalassemia. The current FDA materials specify the indications and associated safety requirements. FDA CASGEVY product page

Sources and scientific literature

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $CRSP or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, court records and market-data providers, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Biotechnology companies face clinical, regulatory, reimbursement, commercialization and financing risks, including dilution, and investors can lose capital. Readers are responsible for their decisions and should consult a licensed financial adviser where appropriate.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.